Biogen (BIIB) Amortizatization of Intangibles (2023 - 2026)

Biogen (BIIB) posted quarterly Amortizatization of Intangibles of $107.6 million for Q1 2026, up 109.34% year-over-year from $51.4 million in Q1 2025, and up 42.71% on a QoQ basis from $75.4 million in Q4 2025.

Biogen (BIIB) Amortizatization of Intangibles (2023 - 2026) Analysis & Trends

Biogen (BIIB) has reported Amortizatization of Intangibles for 4 consecutive years, with $107.6 million the latest figure, recorded in Q1 2026.

  • In Q1 2026, Amortizatization of Intangibles rose 109.34% year-over-year to $107.6 million; the TTM figure through Mar 2026 stood at $297.0 million (up 25.16% YoY), while the FY2025 annual figure was $240.8 million, up 4.7% from the prior year.
  • Amortizatization of Intangibles came in at $107.6 million for Q1 2026 at Biogen, up from $75.4 million in the prior quarter.
  • The five-year high for Amortizatization of Intangibles was $107.6 million in Q1 2026, with the low at $31.5 million in Q4 2023.
  • Average Amortizatization of Intangibles over 4 years is $61.0 million, with a median of $52.0 million recorded in 2025.
  • Across the five-year window, Amortizatization of Intangibles plunged 41.73% in 2025 and jumped 109.34% in 2026, its largest moves.
  • Year by year, Amortizatization of Intangibles stood at $31.5 million in 2023, then jumped by 42.54% to $44.9 million in 2024, then surged by 67.93% to $75.4 million in 2025, then soared by 42.71% to $107.6 million in 2026.
  • According to Business Quant data, Amortizatization of Intangibles over the past three periods registered $107.6 million, $75.4 million, and $61.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Amort. of Intangibles (Qtr)
1 Eli Lilly 1,066.16 Bn 1,060.88 Bn 16.22 Bn -
2 Johnson & Johnson 611.69 Bn 589.64 Bn 15.96 Bn -
3 AbbVie 444.34 Bn 434.99 Bn 10.78 Bn 1.70 Bn
4 Astrazeneca 284.94 Bn 277.05 Bn 12.61 Bn -
5 Merck 224.23 Bn 218.58 Bn 12.09 Bn 931.00 Mn
6 Amgen 195.12 Bn 183.08 Bn 5.87 Bn -
7 Gilead Sciences 156.45 Bn 148.73 Bn 5.52 Bn 596.00 Mn
8 Pfizer 136.01 Bn 123.24 Bn -1.21 Bn -
9 Novartis Ag 113.45 Bn 113.67 Bn - -
10 Biogen 30.87 Bn 26.59 Bn 1.82 Bn 107.60 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 107.60 Mn
Mar 31, 2026 107.60 Mn
Dec 31, 2025 75.40 Mn
Dec 31, 2025 75.40 Mn
Sep 30, 2025 61.50 Mn
Sep 30, 2025 61.50 Mn
Jun 30, 2025 52.50 Mn
Jun 30, 2025 52.50 Mn
Mar 31, 2025 51.40 Mn
Mar 31, 2025 51.40 Mn
Dec 31, 2024 44.90 Mn
Dec 31, 2024 44.90 Mn
Sep 30, 2024 50.90 Mn
Sep 30, 2024 50.90 Mn
Jun 30, 2024 90.10 Mn
Jun 30, 2024 90.10 Mn
Mar 31, 2024 44.10 Mn
Mar 31, 2024 44.10 Mn
Dec 31, 2023 31.50 Mn
Dec 31, 2023 31.50 Mn